Finally, our data suggest that the detected metabolic heterogeneity (the high mTORC2 complex activity, enhanced expression of Rictor, p-Akt, p-S6, CPT1A and LDHA enzymes in glioma cases) is a very promising combination target. The gene discussed is CPT1A; the disease is central nervous system cancer.